MedCity News February 15, 2023
Marissa Plescia

The U.S. Department of Health & Human Services announced three models Tuesday that will be tested by the CMS Innovation Center and aim to lower prescription drug costs. The models, which include access to $2 generic drugs, build on the Inflation Reduction Act of 2022.

The U.S. Department of Health & Human Services (HHS) unveiled three new models Tuesday that will be tested by the CMS Innovation Center and aim to lower prescription drug costs. The models include access to $2 generic drugs.

The news is in response to President Joe Biden’s executive order issued in October, which directed HHS to find ways to lower prescription drug costs and improve access to drug therapies for those enrolled in Medicare and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, HHS, Insurance, Medicare, Patient / Consumer, Payment Models, Pharma, Pharma / Biotech, Provider, Value Based
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Prior authorizations, pharmacy transparency, vertical integration all part of the Medicare 2026 rule
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

Share This Article